Skip to content
2000
Volume 3, Issue 1
  • ISSN: 1872-2156
  • E-ISSN: 2212-3431

Abstract

The mammalian target of rapamycin (mTOR) plays an important role in cell growth. Dysfunction of mTOR has been linked to many human diseases, such as cancers, obesity, diabetes, cardiovascular diseases and neurological disorders. Currently, the mTOR inhibitor rapamycin and its analogs have been vigorously evaluated and developed as anticancer drugs. Here, we will review the most recent patents and patent applications relating to mTOR pathway. Moreover, we will discuss the patents and patent applications on the treatment of mTOR-associated metabolic diseases and cancers.

Loading

Article metrics loading...

/content/journals/dnag/10.2174/187221509787236192
2009-01-01
2025-09-28
Loading full text...

Full text loading...

/content/journals/dnag/10.2174/187221509787236192
Loading

  • Article Type:
    Research Article
Keyword(s): 4EBP1; Akt/PKB; cancer; mTOR; mTORC1; mTORC2; rapamycin; Rheb; S6K; TSC1/TSC2
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test